Every seller on this roster has a dose ladder, published or not, and the reason a reader cares is that climbing it costs money. This trial answers the other half of the question: what climbing it buys. It is unusually well designed for that purpose, because it put the two doses against each other rather than leaving the comparison to be assembled from separate studies — the weakness that undermines most such claims, discussed in tirzepatide against semaglutide.
What was compared
Between January 2023 and November 2024, 1,407 adults with obesity were randomized to semaglutide 7.2 mg, semaglutide 2.4 mg, or placebo [1]. Nearly three-quarters were female, mean age was 47, mean weight 113 kg and mean BMI 39.9.
What the higher dose added
Mean weight change was −18.7% on 7.2 mg against −15.6% on 2.4 mg, an estimated treatment difference of 3.1 percentage points (95% CI −4.7 to −1.6). Against placebo the difference was 14.8 points.
The thresholds show where the extra dose earns its keep. Compared with 2.4 mg, the 7.2 mg arm was 1.8 times likelier to reach a 20% reduction and 2.4 times likelier to reach 25%. At the lower thresholds the two doses were not far apart; the difference is concentrated at the far end.
The number that does not fit
Serious adverse events were reported by 6.8% of the 7.2 mg arm, 10.9% of the 2.4 mg arm and 5.5% of placebo. The highest rate was in the middle dose, which is not what a dose-response relationship looks like.
With 201 participants in that arm against 1,004 in the other, the comparison is fragile and the difference may be noise. It is reported here because leaving it out would tidy the result in the drug’s disfavor, and a page that only prints the numbers that fit its argument is doing the thing this site exists to catch.
What a buyer takes from it
That the ladder has a top, that the top is worth about three points of weight, and that it costs a substantially higher rate of side effects to stand on. Whether a seller will tell you what the top rung costs in money is a separate matter, counted in who publishes a dose ladder and listed seller by seller in published dose ladders.
It is also worth knowing that most people never reach a dose like this. Real-world prescribing settles lower and slower than trial protocols, and a large share stop before the question arises at all — which is the context for everything above, and the subject of stopping and weight regain.